Company PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per region

Ratings for PTC Therapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
24.69 ^USD	-1.87%		-9.89%	-10.41%

Mar. 28	PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment	MT
Mar. 28	PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	CI

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Number of employees: 1,022

USD in Million	2022	Weight	2023	Weight	Delta
Small Molecule and Gene Therapeutics 100.0 %	699	100.0 %	938	100.0 %	+34.20%

USD in Million	2022	Weight	2023	Weight	Delta
United States 56.7 %	499	71.3 %	532	56.7 %	+6.64%
Non-United States 43.3 %	200	28.7 %	406	43.3 %	+102.84%

Managers	Title	Age	Since
Matthew Klein CEO	Chief Executive Officer	52	19-09-30
Pierre Gravier DFI	Director of Finance/CFO	39	23-07-12
Ellen Welch CTO	Chief Tech/Sci/R&D Officer	-	-
Neil Almstead CTO	Chief Tech/Sci/R&D Officer	57	99-12-31
Kylie O'Keefe IRC	Investor Relations Contact	-	18-04-30
Hege Sollie-Zetlmayer HRO	Human Resources Officer	-	17-12-31
Timothy Dyer SEC	Corporate Secretary	-	18-05-31
Marla Weetall PRN	Corporate Officer/Principal	-	02-09-30
Christopher Trotta PRN	Corporate Officer/Principal	-	-
Christine Utter AUD	Comptroller/Controller/Auditor	46	09-12-31

Members of the board	Title	Age	Since
Glenn Steele BRD	Director/Board Member	79	15-06-14
Michael Schmertzler CHM	Chairman	72	01-07-31
David Southwell BRD	Director/Board Member	63	05-11-30
Allan Jacobson FOU	Founder	78	98-03-30
Emma Reeve BRD	Director/Board Member	63	18-12-17
Jerome Zeldis BRD	Director/Board Member	74	12-09-27
Alethia Young BRD	Director/Board Member	45	22-06-08
Matthew Klein CEO	Chief Executive Officer	52	19-09-30
Mary Smith BRD	Director/Board Member	61	21-06-07
Stephanie Okey BRD	Director/Board Member	64	18-12-17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	76,608,030	74,471,532 ( 97.21 %)	0	97.21 %

Name	Equities	%	Valuation
Wellington Management Co. LLP 12.81 %	9,816,603	12.81 %	286 M $
Vanguard Fiduciary Trust Co. 11.49 %	8,800,843	11.49 %	256 M $
RTW Investments LP 9.691 %	7,423,970	9.691 %	216 M $
BlackRock Advisors LLC 9.119 %	6,985,762	9.119 %	203 M $
Armistice Capital LLC 8.960 %	6,864,000	8.960 %	200 M $
STATE STREET CORPORATION 6.049 %	4,633,955	6.049 %	135 M $
Camber Capital Management LP 5.221 %	4,000,000	5.221 %	116 M $
Cowen & Co. LLC 4.863 %	3,725,626	4.863 %	108 M $
Janus Henderson Investors US LLC 3.410 %	2,612,593	3.410 %	76 M $
Fidelity Management & Research Co. LLC 2.368 %	1,814,421	2.368 %	53 M $

Name	Equities	%	Valuation
CLEARPOINT NEURO, INC. 3.32%	894,578	3.32%	6,083,130 $

PTC Therapeutics, Inc.

100 Corporate Court

07080-2449, South Plainfield

+908 222 7000

http://www.ptcbio.com

Name	Category and Sector
PTC Therapeutics International Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

24.69 USD

Average target price

29.17 USD

Spread / Average Target

+18.13%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
PTC THERAPEUTICS, INC.	-10.41%	1.89B
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-1.48%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-8.72%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs